ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs.
rNAPc2 is being developed as a potential treatment for patients hospitalized with COVID-19. ARCA believes rNAPc2’s mechanism of action, along with safety data from prior human clinical trials in over 700 patients, provide a strong scientific rationale supporting evaluation of rNAPc2 as a potential therapeutic treatment for RNA virus associated diseases, including COVID-19.
Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation in patients with heart failure. ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted cardiovascular therapeutic.
Kaleidoscope Data Privacy Consultants SL (KDPC ES) is the EEA Representative for the purposes of the General Data Protection Regulation (GDPR) for ARCA through our office in Barcelona.
If you have a question about how your personal data is processed, please select your preferred language from the menu on the left. Here you will find details on how to contact KDPC ES including a form to request a telephone call or submit your question online.
You can find out more information about ARCA Biopharma by clicking here which takes you to a new site.
Contact details of our office in Spain
Kaleidoscope Data Privacy Consultants SL
Calle Balmes 173, 4-2, Barcelona 08006, Spain
+34 (0) 938 004910 (Note: calls are answered in English. If you are not comfortable with English, please fill out the contact form and we will call you and speak in the language of your choice through an interpreter.)